Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal AC polysaccharide vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Meningococcal AC polysaccharide vaccine is a purified, inactivated vaccine containing capsular polysaccharide antigens from *Neisseria meningitidis* serogroups A and C, designed to stimulate active immunity against invasive meningococcal disease caused by these groups. Unlike conjugate formulations, this vaccine consists of plain polysaccharides rather than antigens linked to protein carriers. The immune response is predominantly T-cell independent, yielding protection for a limited duration and less immunologic memory compared to conjugate vaccines. It is primarily used in outbreak control, travelers to endemic areas, and in certain populations at increased risk where conjugate vaccines are unsuitable. The vaccine does not provide protection against meningococcal serogroup B or other serogroups not included in the formulation[2][6].
- Brand names
- Menomune
- Other names
- meningococcal polysaccharide vaccineMPSV4MPSV-4MPSV 4
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal AC polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal AC polysaccharide vaccine.